

CAR-T patient card for ciltacabtagene autoleucel

Please fill in your information and keep this card with you at all times. In the event of an emergency, call the numbers provided below and go to the CAR-T centre or local hospital right away. Show this card to any healthcare practitioner that sees you if you must go to a hospital outside of your normal treatment visits.

CUT HERE

Patient Card CARVYKT[®] (ciltacabtagene autoleucel)
 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

PATIENT'S NAME: _____

Emergency Contact

PATIENT CAREGIVER'S NAME: _____ **PATIENT CAREGIVER'S PHONE NUMBER:** _____

FOLD HERE

Primary CAR-T Healthcare Provider

HEALTHCARE PROVIDER'S NAME: _____ **HEALTHCARE PROVIDER'S PHONE NUMBER:** _____

CAR-T CENTER ADDRESS: _____ **CAR-T CENTER PHONE NUMBER:** _____

FOLD HERE

Important Information for Patients

Carry this card with you at all times. Show it to any doctor who sees you and when you go to the hospital. Tell any healthcare provider who sees you that you are being treated with ciltacabtagene autoleucel.

Plan to stay near the hospital where you were treated for at least 4 weeks after you have ciltacabtagene autoleucel.

Do not drive or use tools or machines until at least 4 weeks after ciltacabtagene autoleucel infusion. Refer to the Patient Information Leaflet for more information.

FOLD HERE

If you experience any newly occurring symptoms, especially any of the symptoms listed on this card, please immediately notify your physician, your treating healthcare provider, or any healthcare provider available.

Ciltacabtagene autoleucel can cause serious side effects in different parts of your body. These symptoms can be life-threatening or even fatal and need to be addressed immediately.

Symptoms that appear mild may quickly worsen. Symptoms may be delayed and may occur weeks after your infusion.

CUT HERE

Call your treating healthcare provider straight away if you have any of these symptoms:

<p>CRS</p> <p>Fever (38°C or higher)</p> <p>Chills</p> <p>Fast heart beat</p> <p>Difficulty breathing</p> <p>Feeling dizzy or lightheaded</p>	<p>Neurologic toxicity</p> <p>Feeling confused, less alert or disorientated</p> <p>Having difficulty speaking</p> <p>Having difficulty reading or writing</p> <p>Loss of coordination</p> <p>Personality changes</p>
--	---

FOLD HERE

Information for Healthcare Team to Fill In

Please give this card to your CAR-T healthcare team to fill in the information and return to you.

ON (DATE) _____

this patient received ciltacabtagene autoleucel, which is a chimeric antigen receptor T cell therapy (CAR-T therapy) for multiple myeloma.

(BATCH ID) _____

FOLD HERE

Important Information for Healthcare Providers

This patient has received an engineered autologous T-cell immunotherapy product that can lead to severe and even fatal cytokine release syndrome (CRS) and neurologic toxicity. Assess the patient for signs and symptoms of CRS and neurologic toxicity.

See Summary of Product Characteristics for full details.

FOLD HERE

Before providing any treatment, call the primary healthcare provider at the number on the front of the card. This patient should not donate blood, organs, tissues or cells for transplantation.

Address events reporting guidelines:
 SFDA (National Pharmacovigilance Center)
 Email: spcdrug@sfda.gov.sa
 Telephone: 19020702
 Fax: 19020702
 Online: <http://eda.sfd.gov.sa>

For full prescribing information, please refer to the datasheet or contact Johnson & Johnson Middle East FZ LLC (Riyadh)
 Address: Prince Mohammed Bin Abdulaziz Rd., Tower E, Level 30, Olaya towers,
 Giza City, 10961, P.O. Box 1329, Riyadh, 11458, Saudi Arabia
 To Report Adverse Events/Product Complaint or any Medical Information Inquiries,
 please contact us at:
medinfo@car-t.com
 Hotline: 00966820013811